Hysterectomy by Transvaginal Natural Orifice Transluminal Endoscopic Surgery Versus or Laparoscopic Hysterectomy

NCT ID: NCT05884658

Last Updated: 2024-12-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-12-23

Study Completion Date

2026-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In France, there are approximately 62,000 hysterectomies per year, 70% of which are benign. It is the most frequent surgical procedure in gynecology.

Hysterectomies are performed via 3 routes: laparotomy, laparoscopy or vaginal route.

This choice of approach is particularly important in the case of large uteri (50% of uteri \> 280g), which increase the risks of laparoconversion and bladder injury (NP3).

The vaginal route reduces the operating time and postoperative pain. Laparoscopy allows a better anatomical view and easier access to the neighbouring organs, which makes it the preferred approach, especially for young surgeons and when the uterus is large. However, the laparoscopic route is associated with an increase in the rate of conversion to laparotomy according to the volume of the uterus, as well as the rate of general per and postoperative complications compared with vaginal hysterectomy for uteri \> 280 g. In a meta-analysis comparing laparoscopy and vaginal hysterectomy, the total prevalence of perioperative complications according to the classification of Clavien and Dindo was 27%. For large uteruses, complications by the vaginal route amounted to 15% and those by the laparoscopic route to 37.5%.

The data are not sufficient to give preference to one or other of the approaches, but for benign pathologies, for large uteri (\>280 g), the minimally invasive laparoscopic or vaginal approaches are recommended by the CNGOF (grade C).

A new Medical Device (MD), the vNOTES (Vaginal Natural Orifice Transluminal Endoscopy System) offers the advantage of two approaches for pelvic surgery by allowing minimally invasive surgery to be performed by endoscopy through the vagina, offering perfect vision for the assistants and the operator and without scarring. Two randomized trials have shown that vNOTES allows, compared to laparoscopy, to perform adnexectomies and hysterectomies without conversion with less pain, fewer postoperative complications and a shorter hospitalization time.

The first evaluations of vNOTES are encouraging and suggest a new era for pelvic surgery: less postoperative pain, fewer complications and facilitation of ambulatory care. Also the videoscopic assistance of the vNOTES is a pedagogical tool for the vaginal route because the field of vision is no longer limited to the operator alone. However, the vNOTES has only been evaluated by the developers of the tool, in monocentric studies and in small numbers. The hysterectomy study evaluated only 35 patients with vNOTES, half of whom had a uterus of less than 280 g. The benefit of vNOTES for uteri smaller than 280 g is not obvious because of the ease of the surgical procedure and the cost of the "classic" vaginal route. Our study would be the first multicentric and academic study on vNOTES to focus specifically on large volume uteri, the most difficult to operate and prone to postoperative complications.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hysterectomy, Vaginal

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

natural orifice transluminal endoscopy system large uteri

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

prospective, multicenter, randomized, parallel-group, non-inferiority open superiority study
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

laparoscopic hysterectomy

Laparoscopic Hysterectomy will be performed in a standardized manner with or without surgical robot

Group Type ACTIVE_COMPARATOR

laparoscopic hysterectomy

Intervention Type PROCEDURE

laparoscopic hysterectomy uses a standardized procedure with or without surgical robot

natural vaginal orifice transluminal endoscopic system for hysterectomies (vNOTES)

Vaginal hysterectomy will be performed in a standardized manner using transluminal endoscopic system

Group Type EXPERIMENTAL

vNOTES : natural vaginal orifice transluminal endoscopic system for hysterectomies

Intervention Type PROCEDURE

hysterectomy via the vaginal approach by vNOTES (natural vaginal orifice transluminal endoscopic system for hysterectomies)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

vNOTES : natural vaginal orifice transluminal endoscopic system for hysterectomies

hysterectomy via the vaginal approach by vNOTES (natural vaginal orifice transluminal endoscopic system for hysterectomies)

Intervention Type PROCEDURE

laparoscopic hysterectomy

laparoscopic hysterectomy uses a standardized procedure with or without surgical robot

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Any woman received in preoperative consultation in the Gynecology-Obstetrics Department for a benign pathology of a uterus estimated to be large requiring a hysterectomy.
* Patient affiliated or entitled to a social security system
* Patients over 18 years of age
* Patients having given their agreement to participate and after signing the consent form

Exclusion Criteria

* Woman refusing to participate in the study (lack of consent)
* Non-French speaking woman (unable to conduct a good quality interview of the pregnant woman)
* Participation in another interventional study.
* Patient subject to a legal protection measure or unable to express her consent
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ministry of Health, France

OTHER_GOV

Sponsor Role collaborator

Centre Hospitalier Universitaire de Saint Etienne

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Céline CHAULEUR, PhD

Role: PRINCIPAL_INVESTIGATOR

CHU SAINT-ETIENNE

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

HFME - Hospices Civils de Lyon

Bron, , France

Site Status NOT_YET_RECRUITING

CHU Clermont-Ferrand

Clermont-Ferrand, , France

Site Status RECRUITING

Ch Issoire

Issoire, , France

Site Status NOT_YET_RECRUITING

CHU Saint-Etienne

Saint-Etienne, , France

Site Status NOT_YET_RECRUITING

Clinique Mutualiste de Saint-Etienne

Saint-Etienne, , France

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Céline CHAULEUR, PhD

Role: CONTACT

Phone: 0477828383

Email: [email protected]

Florence RANCON

Role: CONTACT

Phone: 0477829458

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Géry LAMBLIN

Role: primary

Sandrine CAMPAGNE-LOISEAU, PH

Role: primary

Aslam MANSOOR

Role: primary

Céline CHAULEUR, PhD

Role: primary

Quentin REBOUL, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023-A01013-42

Identifier Type: OTHER

Identifier Source: secondary_id

21PH265

Identifier Type: -

Identifier Source: org_study_id